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Alzheimer’s disease (AD) is a progressive neurodegenerative disorder pathologically characterized by deposition of -amyloid (A)
peptides as senile plaques in the brain. Recent studies suggest that green tea flavonoidsmay be used for the prevention and treatment of
a variety of neurodegenerative diseases. Here, we report that (-)-epigallocatechin-3-gallate (EGCG), themain polyphenolic constituent of
green tea, reduces A generation in bothmurine neuron-like cells (N2a) transfected with the human “Swedish”mutant amyloid precur-
sor protein (APP) and in primary neurons derived from Swedishmutant APP-overexpressingmice (Tg APPsw line 2576). In concert with
these observations,we find that EGCGmarkedly promotes cleavage of the-C-terminal fragment ofAPPandelevates theN-terminalAPP
cleavage product, soluble APP-. These cleavage events are associated with elevated -secretase activity and enhanced hydrolysis of
tumor necrosis factor -converting enzyme, a primary candidate -secretase. As a validation of these findings in vivo, we treated Tg
APPsw transgenic mice overproducing A with EGCG and found decreased A levels and plaques associated with promotion of the
nonamyloidogenic -secretase proteolytic pathway. These data raise the possibility that EGCG dietary supplementation may provide
effective prophylaxis for AD.
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Introduction
Amyloid precursor protein (APP) proteolysis is the fundamental
process for the production of -amyloid (A) peptides impli-
cated in Alzheimer’s disease (AD) pathology (Golde et al., 2000;
Huse and Doms, 2000; Sambamurti et al., 2002; Funamoto et al.,
2004). APP proteolytic products arise from the coordinated ac-
tion of -, -, and -secretases. In the amyloidogenic pathway,
A peptides are produced by the initial action of -secretase
(BACE) cleaveage, which creates an A-containing C-terminal
fragment (CTF) known as -CTF or C99 (Sinha and Lieberburg,
1999; Yan et al., 1999). This proteolysis also generates an
N-terminal, soluble APP- (sAPP-) fragment, which is released
extracellularly. Intracellularly, -CTF is then cleaved by a multi-
protein -secretase complex that results in generation of the A
peptide and a smaller -CTF, also known as C57 (De Strooper et
al., 1998; Steiner et al., 1999). Conversely, in the nonamyloido-
genic pathway, APP is first cleaved at the -secretase site, which
results in the release of N-terminal sAPP- and the generation of
-CTF or C83 (Hooper and Turner, 2002), events that are indic-
ative of -secretase activity (Hooper and Turner, 2002). Because
of the limiting amount of APP in the cell and the failure to satu-
rate the BACE pathway during APP overexpression, it is believed
that the above-mentioned amyloidogenic and nonamyloido-
genic pathways compete for substrate in the process of APP pro-
teolysis (Gandhi et al., 2004). Therefore, it is often inferred that
extracellular elevation of sAPP- (resulting from nonamyloido-
genic pathway activation) can be taken as indirect evidence of
inhibition of BACE and the associated amyloidogenic pathway.
However, because the extracellular secretion of these various
fragments can be regulated independently of APP cleavage, it is
important to fully characterize the effects of treatment on both
pathways concurrently before making inferences about underly-
ing mechanisms (Rossner et al., 2000).
Over the past decade, intense focus has been given to investi-
gating the processes of APP proteolysis and A metabolism as
possible targets for AD therapy (Hardy and Selkoe, 2002). Vari-
ous synthetic and naturally occurring compounds have been an-
alyzed for their efficacy in the modulation of these pathological
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events. One such naturally occurring compound achieving
worldwide popularity for its therapeutic application is green tea.
Green tea contains polyphenolic structures categorized as fla-
vonoids, which are believed to be the active components account-
ing for the therapeutic properties of green tea. Arguably, one of
the most promising green tea compounds being analyzed is
(-)-epigallocatechin-3-gallate (EGCG), which has been exten-
sively studied primarily because of its reported anticarcinogenic
effects (Lin and Liang, 2000;Moyers andKumar, 2004). Recently,
EGCG has been found to modulate protein kinase C (PKC) ac-
tivity and to consequently increase secreted levels of sAPP-
(Levites et al., 2002; Levites et al., 2003). Additionally, EGCG has
been shown to inhibit various activities of proinflammatory cyto-
kines (Ahmed et al., 2002; Han, 2003; Li et al., 2004). Accordingly,
signal transducer and activator of transcription 1 and nuclear factor
B responses are inhibited by EGCG (Han, 2003; Aktas et al., 2004).
Elucidation of these molecular actions of EGCG substantiates the
compound as a versatile modulator of cellular responses that may
contribute to disease pathogenesis.
In the present study, we demonstrate that EGCG treatment of
both murine N2a cells transfected with the human “Swedish”
mutant form of APP (SweAPP N2a cells) and primary neuronal
cells derived from Alzheimer Swedish mutant APP overexpress-
ing mice (Tg APPsw line 2576) (Hsiao et al., 1996) leads to a
significant reduction in A production. Furthermore, Tg APPsw
mice treatedwith EGCG showdecreasedA levels and-amyloid
plaques in the brain. These effects are associatedwith increased gen-
eration of -CTF and sAPP- and elevated -secretase cleavage ac-
tivity, showing that EGCG promotes the nonamyloidogenic
-secretase proteolytic pathway both in vitro and in vivo.
Materials andMethods
Reagents.Green tea-derived flavonoids (95%purity byHPLC), includ-
ing EGCG, (-) EC, () EC, GC, and C, were purchased from Sigma (St.
Louis, MO). Tumor necrosis factor- (TNF-) protease inhibitor-1
(TAPI-1) and -secretase inhibitor were obtained from Calbiochem
(San Diego, CA). Green tea extract (75% polyphenols) was obtained
from the Vitamin Shoppe (North Bergen, NJ). Antibody against the C
terminus of APP was obtained from Chemicon (Temecula, CA), and
those against the N terminus of APP (22C11) and against actin were
purchased from Roche (Basel, Switzerland).
ELISA. Cultured cells were lysed in ice-cold lysis buffer (20 mM Tris,
pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% v/v Triton X-100,
2.5 mM sodium pyrophosphate, 1 mM -glycerolphosphate, 1 mM
Na3VO4, 1g/ml leupeptin, 1mMPMSF) as described previously (Tan et
al., 2002).Mouse brains were isolated under sterile conditions on ice and
placed in ice-cold lysis buffer. Brains were then sonicated on ice for3
min, allowed to stand for 15 min at 4°C, and centrifuged at 15,000 rpm
for 15 min. A1–40,42 species were detected by acid extraction of brain
homogenates in 5 M guanidine buffer (Johnson-Wood et al., 1997), fol-
lowed by a 1:10 dilution in lysis buffer. Soluble A1–40, 42 was directly
detected in cultured cell lysates or brain homogenates prepared with lysis
buffer described above by a 1:4 or 1:10 dilution, respectively. A1–40,42
was quantified in these samples using the A1–40,42 ELISA kits (IBL-
American, Minneapolis, MN) in accordance with the instructions of the
manufacturer, except that standards included 0.5 M guanidine buffer in
some cases.
Western blot and immunoprecipitation. Cultured cells or mouse brains
were lysed in ice-cold lysis buffer described above, and an aliquot corre-
sponding to 50 g of total protein was electrophoretically separated us-
ing 16.5% Tris-tricine gels. Electrophoresed proteins were then trans-
ferred to polyvinylidene difluoride membranes (Bio-Rad, Richmond,
CA), washed in dH2O, and blocked for 2 h at ambient temperature in
Tris-buffered saline (TBS; Bio-Rad) containing 5% (w/v) nonfat dry
milk. After blocking, membranes were hybridized for 2 h at ambient
temperature with various primary antibodies. Membranes were then
washed three times for 5 min each in dH2O and incubated for 1 h at
ambient temperature with the appropriate HRP-conjugated secondary
antibody (1:1000; Pierce Biotechnology, Rockford, IL). All antibodies
were diluted in TBS containing 5% (w/v) nonfat dry milk. Blots were
developed using the luminol reagent (Pierce Biotechnology). Densito-
metric analysis was done as described previously using a FluorS Multi-
imager with Quantity One software (Bio-Rad) (Tan et al., 2002). Immu-
noprecipitationwas performed for detection of sAPP-, sAPP-, andA
by incubating 200g of total protein of each samplewith various sequen-
tial combinations of 6E10 (1:100; Signet Laboratories, Dedham, MA)
and/or 22C11 (1:100; Roche) antibodies overnight with gentle rocking at
4°C and 10 l of 50% protein A-Sepharose beads were then added to the
sample (1:10; Sigma) before gentle rocking for an additional 4 h at 4°C.
After washes with 1 cell lysis buffer, samples were subjected toWestern
blot analysis as described above. Antibodies used for Western blot anal-
ysis included the APP-C-terminal antibody 369 (1:1000), C-terminal
APP antibody (1:500; Calbiochem), N-terminal APP antibody (clone
22C11), N-terminal A antibodies BAM-10 (-amyloid 10) (1:1000;
Sigma) or 6E10 (1:1000; Signet Laboratories), ADAM-10 (a disintegrin
and metalloprotease 10) antibody (Calbiochem), TNF- converting en-
zyme (TACE) antibody (Calbiochem), or actin antibody (1:1500; as an
internal reference control; Roche). -, -, and -secretase activities were
quantified in cell lysates and mouse brain homogenates using available
kits based on secretase-specific peptides conjugated to fluorogenic re-
porter molecules (R&D Systems, Minneapolis, MN).
Mice. Tg APPsw mice (line 2576) were purchased from Taconic (Ger-
mantown, NY). For intraperitoneal administration of EGCG, a total of
10 female Tg APPsw mice were used; five mice received EGCG, and the
other five received PBS. Beginning at 12 months of age, Tg APPsw mice
were intraperitoneally injected with EGCG (20 mg/kg) or PBS daily for
60 d based on methods described previously (Chyu et al., 2004). These
micewere then killed at 14months of age for analyses of A levels andA
load in the brain according to methods described previously (Tan et al.,
2002). In an additional experiment, 10 female TgAPPswmice at 7months
of age were subjected to a similar treatment regimen as described above,
in which six mice received EGCG and the other four received PBS. These
mice were killed at 9months of age for analysis of amyloidosis (Tan et al.,
2002). For intracerebroventricular injection (n  3 females for each
group), mice were injected in the lateral ventricle with EGCG [(5 l (10
g)/mouse)] or PBS once (Tan et al., 2002; Chauhan and Siegel, 2003).
Twenty-four hours after injection, these mice were killed for analysis of
cerebral A levels as described previously (Tan et al., 2002). Animals
were housed and maintained at the College of Medicine Animal Facility
of the University of South Florida, and all experiments were in compli-
ance with protocols approved by the University of South Florida Institu-
tional Animal Care and Use Committee.
Immunohistochemistry. Mice were anesthetized with isofluorane and
transcardially perfusedwith ice-cold physiological saline containing hep-
arin (10U/ml). Brains were rapidly isolated and quartered using amouse
brain slicer (Muromachi Kikai, Tokyo, Japan). The first and second an-
terior quarters were homogenized for Western blot analysis, and the
third and fourth posterior quarters were used for microtome or cryostat
sectioning. Brains were then fixed in 4%paraformaldehyde in PBS at 4°C
overnight and routinely processed in paraffin in a core facility at the
Department of Pathology (University of South Florida College of Medi-
cine). Five coronal sections from each brain (5 m thickness) were cut
with a 150 m interval. Sections were routinely deparaffinized and hy-
drated in a graded series of ethanol before preblocking for 30 min at
ambient temperature with serum-free protein block (Dako Cytomation,
Carpinteria, CA). A immunohistochemical staining was performed us-
ing anti-human amyloid- antibody (clone 4G8; 1:100; Signet Labora-
tories) in conjunction with the VectaStain Elite ABC kit (Vector Labora-
tories, Burlingame, CA) coupled with diaminobenzidine substrate. 4G8-
positive A deposits were examined under bright field using anOlympus
(Tokyo, Japan) BX-51 microscope. For thioflavin S histochemistry, sec-
tions were routinely deparaffinized and rinsed in 70% (v/v) ethanol be-
fore staining with fresh-filtered 1% (w/v) thioflavin S diluted in 70%
ethanol for 5 min. These sections were rinsed three times for 5 min each
in 70% ethanol, hydrated for 5 min in PBS, and mounted in Vectashield
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fluorescence mounting media (Vector Laboratories). Thioflavin
S-positive -amyloid plaques were visualized under dark field using an
Olympus BX-51 microscope.
Image analysis. Quantitative image analysis (conventional “A bur-
den” analysis) was performed for 4G8 immunohistochemistry and thio-
flavin S histochemistry in Tg APPsw mice injected with EGCG or PBS.
Images were obtained using an Olympus BX-51 microscope and digi-
tized using an attached MagnaFire imaging system (Olympus). Briefly,
images of five 5 m sections (150 m apart) through each anatomic
region of interest (hippocampus or cortical areas) were captured, and a
threshold optical density was obtained that discriminated staining from
background. Manual editing of each field was used to eliminate artifacts.
Data are reported as a percentage of immunolabeled area captured (pos-
itive pixels) divided by the full area captured (total pixels). Quantitative
image analysis was performed by a single examiner (T.M.) blinded to
sample identities.
Statistical analysis. All data were normally distributed; therefore, in
instances of single mean comparisons, Levene’s test for equality of vari-
ances followed by a t test for independent samples was used to assess
significance. In instances of multiple mean comparisons, ANOVA was
used, followed by post hoc comparison using Bonferonni’s method. 
Levels were set at 0.05 for all analyses. The statistical package for the social
sciences release 10.0.5 (SPSS, Chicago, IL) was used for all data analyses.
Results
EGCG inhibits A1–40,42 generation from SweAPP N2a cells
and Tg APPsw mouse-derived primary neuronal cells
HPLC analysis of green tea shows that EGCG is the main poly-
phenolic constituent, although other compounds, including (-)-
epicatechin [(-) EC], ()-epicatechin [() EC], (-)-gallo-
catechin (GC), and (-)-catechin (C), are present in relatively
lesser quantities (Moyers and Kumar, 2004). To examine the
effects of the polyphenolic constituents of green tea onAPP cleav-
age, we first treated SweAPPN2a cells and primary neuronal cells
derived from Tg APPsw mice with a wide
dose range of each of these compounds.
We found that EGCG reduces A genera-
tion (both A1–40 and A1–42 peptides) in
either SweAPP N2a cells or primary Tg
APPsw-derived neuronal cells in a dose-
dependent manner (Fig. 1a,b). Most im-
portantly, EGCG (20M) reduces A gen-
eration from SweAPP N2a cells by 61%
(Fig. 1a) and from primary Tg APPsw-
derived neuronal cells by 38% (Fig. 1b)
compared with untreated cells. It should
be noted that both enantiomeric species of
another green tea component, EC, inhibit
A generation by nearly 20–30% in both
cell types, albeit at relatively high doses
(Fig. 1a,b). However, two other compo-
nents of green tea, GC and C, modestly
promote A production by 20–30%
(for SweAPP N2a cells) or 10–15% (for
primary Tg APPsw-derived neuronal cells)
at a relatively high (80 M) concentration.
To test whetherGC and/orC could oppose
the inhibition of A generation by EGCG,
SweAPP N2a cells were cotreated with
EGCG (20 M) plus GC (80 M), C (80
M), or both for 12 h. As expected, data
show that the presence of GC or C, and
particularly the combination of both,
markedly inhibits the ability of EGCG to
reduce A generation from SweAPP N2a
cells (Fig. 1c). Thus, these data suggest that
a purified preparation of EGCG is more capable of reducing A
generation in vitro than when it is present in a mixture in whole
green tea extract (GT). To further address this hypothesis, we incu-
bated SweAPPN2a cells withGT at various doses andwith a similar
dose of EGCGaspresent inGT.As shown inFigure 1d, data indicate
that the various levels ofEGCGalone elicitmoreprofoundeffects on
reduction ofA generation versuswholeGT.Thus, the ability of the
purified EGCG alone to inhibit A generation is much greater than
that of GT.
EGCG activates nonamyloidogenic processing of APP in
SweAPP N2a cells
To elucidate themode of action of green tea components on APP
cleavage, we examined APP cleavage profiles after treatment of
SweAPPN2a cells with EGCG, EC, GC, andC usingWestern blot
and immunoprecipitation analyses. In concert with reduced A
generation (Fig. 1a,b), EGCG treatment results in greatly in-
creased nonamyloidogenic -CTF generation and augmented
-CTF to -CTF band density ratio in cell lysates (Fig. 2a). Ac-
cordingly, sAPP- (but not sAPP-) is elevated in SweAPP N2a
cell culturemedia (Fig. 2b), an effect that is clearly associatedwith
increased -CTF in corresponding cell lysates after the treatment
(Fig. 2c). Most notably, these effects are both time and dose de-
pendent (Fig. 2c,d). Additionally, as shown in Figure 2e (lower
left) (-) EC treatment only increases -CTF generation at high
doses (similar results were obtained with () EC; data not
shown). In contrast, bothGC andC treatment result in decreased
-CTF relative to -CTF at 80 M as indicated (Fig. 2e, right).
More importantly, at this dose, GC, C, or GC/C significantly
oppose the effect of EGCG on -CTF cleavage (Fig. 2f). In agree-
ment with A ELISA data as shown in Figure 1d, purified EGCG
Figure1. EGCG treatment inhibits A generation in cultured neuronal cells. A1–40,42 peptideswere analyzed in conditioned
media from SweAPP N2a cells (a, c, d) or Tg APPswmouse-derived primary neurons (b) by ELISA (n 3 for each condition). Data
are represented as a percentage of A1–40,42 peptides secreted 12 h after EGCG treatment relative to control (untreated). a, b,
One-way ANOVA followed by post hoc comparison revealed significant differences between EGCG and the other compounds at 40,
20, 10, and 5 M treatment concentrations ( p 0.001). c, When comparing EGCG (20 M) treatment with cotreatment of
SweAPP N2a cells with EGCG (20M) plus GC (80M), C (80M), or GC/C, a significant differencewas noted for each comparison
( p 0.001).d, SweAPPN2a cells were treatedwith EGCG at a comparable concentrationwith that found in GT (GT contains 30%
EGCG), and a significant difference was noted between GT and EGCG treatments (40g/ml vs 20M; 20g/ml vs 10M; 10
g/ml vs 5M) on inhibition of A generation ( p 0.001 for each comparison). Reduction for each treatment condition is
indicated for c and d.
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demonstrates a marked effect on -CTF
generation versus an equivalent amount of
GT (Fig. 2g). It should be noted that we did
not observe changes in full-length holo
APP expression after any of these treat-
ments (see Western blot analysis as shown
in Fig. 2), suggesting that these treatments
promote nonamyloidogenic APP cleavage
as opposed to altered APP expression in
SweAPP N2a cells.
EGCG promotes -secretase cleavage of
APP in SweAPP N2a cells
As illustrated in Figure 2c, Western blot
analysis clearly shows a time-dependent
increase in -CTF generation in EGCG-
treated SweAPP N2a cells. Most notably,
-CTF generation dramatically increases
at 3–4 h up to 8 h after EGCG treatment.
To test whether the alteration of APP
-CTF was attributable to enhanced
-secretase cleavage activity, we first ex-
amined expression of TACE, an APP
-secretase candidate (Skovronsky et al.,
2001; Allinson et al., 2003), in cell lysates
byWestern blot analysis. Results show that
TACE expression is significantly increased
at 2–4 h after EGCG treatment and then
rapidly degraded through to 8 h (Fig. 3a).
To test whether this EGCG-induced alter-
ation in TACE expression correlated with
modulation of -secretase cleavage activ-
ity, we evaluated the latter in cell lysates
prepared from EGCG-treated or vehicle
(PBS)-treated SweAPP N2a cells. Results
reveal that -secretase cleavage activity is
markedly elevated at the first 1–3 h after
EGCG treatment of SweAPP N2a cells
(Fig. 3b). Finally, we cotreated SweAPP
N2a cells with EGCG and TAPI-1, a selec-
tive TACE inhibitor (Slack et al., 2001;
Robert et al., 2005), for 4 h. Data show that
the presence of TAPI-1 significantly di-
minishes the ability of EGCG to increase
Figure2. EGCG treatment alters APP cleavage in vitro.a,b, SweAPPN2a cellswere treatedwith EGCGat 20Mor PBS (control)
for 12 h. Cell lysates were prepared and subjected to Western blot (WB) analysis of APP CTFs (a), and conditioned media were
collected for immunoprecipitation (IP)/WB (b). c,d, Cell lysateswere prepared fromSweAPPN2a cells treatedwith EGCGat 20M
for a range of timepoints (c) or EGCGat various doses for 12h (d) and subjected toWB for APPCTFs.e,g, Cell lysateswere prepared
from SweAPP N2a cells treatedwith EGCG (-) EC, () EC, GC, C, or GT at the doses indicated for 12 h. For f, SweAPP N2a cells were
cotreated with EGCG (20M) and GC, C, or GC/C at 80M for 12 h. For a and c–g, WB analysis using antibody 369 against the
4
cytoplasmic tail of APP shows full-length holo APP and two
bands corresponding to-CTF (C99) and-CTF (C83). For b,
WB analysis using antibody 22C11 against the N terminus of
APP shows sAPP- (IP with antibody 6E10 directed against
A1–17) and sAPP- [following immunodepletion (ID) with
6E10 and subsequent IP with 22C11]. a, c, d, g, Western blot
analysis with anti-actin antibody shows actin protein (as an
internal reference control). Densitometry analysis shows the
ratio of-CTF to-CTF as indicated below the figures. a, A t
test revealed a significant difference between EGCG treatment
and control (n 3 for each condition; p 0.001). f, One-way
ANOVA showed significant between-groups differences ( p
0.01) with n 4 for each condition, and post hoc comparison
revealed a significant difference between EGCG and EGCG/
GC/C treatments ( p 0.001). Similar results were observed
in N2a cells transfected with human wild-type APP695 using
369 antibody and in SweAPP N2a cells using Calbiochempoly-
clonal APP C-terminal APP antibody (data not shown).
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-CTF generation (Fig. 3c), attenuates EGCG-induced elevation
of -secretase cleavage activity (Fig. 3d), and blunts EGCG-
mediated reduction of detergent-soluble A (Fig. 3e). Together,
these data suggest that elevation of TACE expression in response
to EGCG treatment is likely responsible for increased -secretase
activity in SweAPP N2a cells.
Treatment of Tg APPsw mice with EGCG results in
nonamyloidogenic APP processing and reduction of
cerebral amyloidosis
We validated in vivo whether EGCG treatment could promote
nonamyloidogenic APP processing/-secretase proteolysis and
impact cerebral A levels/-amyloid plaques in Alzheimer trans-
genic mice. We intraperitoneally administered EGCG to Tg
APPswmice, a well-established transgenicmousemodel of AD, at
an age when A deposits are accumulating (12 months). EGCG
was administered based on a treatment schedule that produces
benefit in an atherosclerosis mouse model (Chyu et al., 2004). Tg
APPsw mice at 12 months of age were intraperitoneally injected
with EGCG or PBS daily for 60 d. Nonamyloidogenic APP frag-
ments, including -CTF and sAPP-, are markedly increased in
brains of Tg APPswmice treated with EGCG versus PBS (Fig. 4a).
Accordingly, both detergent soluble A1–40, 42 levels are reduced
by54 and 44%, respectively; and insoluble A1–40, 42 (prepared
by acid extraction in 5 M guanidine) levels are reduced by 47 and
38%, respectively, in EGCG-treated Tg APPsw mice, as deter-
mined by A ELISAs (Fig. 4b,c). A similar magnitude of reduc-
tion was noted when considering each A species alone (data not
shown).We also found an40% increase in-secretase cleavage
activity (Fig. 4d) that was inversely associated with reduced total
A levels.
The above data suggest that EGCG may act as an -secretase
agonist in a transgenicmousemodel of AD. Yet, because EGCGwas
administered intraperitoneally, we tested whether these EGCG ef-
fects are attributable to action of the compound in the periphery
and/or the CNS.We administered EGCG intracerebroventricularly
to Tg APPsw mice. With this treatment regimen, EGCG-treated Tg
APPswmice show significant reduction in cerebral detergent soluble
A1–40,42 levels by 39% [384.65 22.49 vs 235.60 13.04 (mean
pg/mg total protein  SEM)], an effect that is associated with in-
creased production of -CTF/sAPP- (data not shown), and ele-
vated -secretase cleavage activity by 32% [601.8  38.13 vs
890.29  104.41 (mean fluorescence units/mg total protein 
SEM)]. Importantly, cerebral soluble A1–40,42 levels are reduced by
a comparable magnitude in Tg APPsw mice treated with EGCG via
intracerebroventricular and intraperitoneal routes, suggesting that
the in vivo effect of EGCG on nonamyloidogenic processing of APP
is mainly owed to CNS action of the compound.
Finally, we examined -amyloid plaques by 4G8 immunohis-
tochemistry and thioflavin S histochemistry in brains ofmice that
received peripheral injection of EGCG or vehicle (PBS) (Fig.
4e,g). At 14 months of age, 4G8 immunoreactive and thioflavin
S-positive A deposits were significantly reduced by 47–54%
(Fig. 4f) and 35–46% (Fig. 4h) across the hippocampal and cor-
tical brain regions examined. These data are supported by A
ELISA results examining insoluble 5 M guanidine-extracted brain
homogenates, in which a 41% reduction was noted (Fig. 4c).
Together, the above lines of evidence demonstrate that EGCG
promotes nonamyloidogenic processing of APP and attenuates
cerebral amyloidosis in a transgenic mouse model of AD.
Discussion
Previous reports have shown that green tea components such as
EGCGhave neuroprotective properties; however, a clear cellular/
Figure3. EGCG treatment promotes-secretase cleavage of APP in vitro.a,b, Cell lysateswere prepared fromSweAPPN2a cells treatedwith EGCG (20M) for different time points as indicated.
a, Western blot analysis by anti-TACE antibody shows TACE and cleaved fragments. b, -, -, and -secretase cleavage activities were analyzed in cell lysates using secretase cleavage activity
assays. Data are presented as a percentage of fluorescence units/milligrams protein activated 1, 2, or 3 h after EGCG treatment relative to control (PBS). A t test revealed a significant difference
between-secretase and either- or-secretase cleavage activity at 1, 2, and 3 h after EGCG treatment ( p 0.001). c– e, SweAPP N2a cells were treated with EGCG (20M) or PBS (control) in
the presence or absence of TAPI-1 at various doses (c) or at 25M (d, e) for 4 h. Cell-cultured supernatantswere collected, and cell lysateswere prepared from cultured cells. c, Western blot analysis
by antibody 369 shows holo APP and two bands corresponding to -CTF and -CTF. d, Data are represented as percentage of -secretase cleavage activity calculated in terms of fluorescence
units/milligrams protein after EGCG treatment relative to control (PBS) 4 h after EGCG treatment in the presence or absence of TAPI-1. A t test revealed a significant difference between EGCG
treatment and cotreatment with EGCG and TAPI-1 ( p 0.001); increased levels of activity are indicated. e, Data are presented as percentage of A secretion relative to PBS control 4 h after EGCG
treatment in the presence or absence of TAPI-1. A t test revealed a significant difference between EGCG and EGCG plus TAPI-1 treatment ( p 0.001); reduction for each treatment condition is
indicated.
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Figure4. EGCGpromotes nonamyloidogenic APPprocessing and reduces cerebral amyloidosis in TgAPPswmice. Brain homogenateswere prepared from female TgAPPswmice treatedwith EGCG
(n 11) or PBS (n 9).a, Top,Western blot analysis by antibody 369 shows holo APP and two bands corresponding to-CTF and-CTF.a, Middle and bottom,Western blot analysis by antibody
22C11 shows holo APP (middle; following ID/C-terminal APP antibody) and sAPP- (bottom; following ID/C-terminal APP antibody and IP/6E10). Detergent-soluble (Figure legend continues.)
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molecular mechanism underlying these effects has hitherto not
been established (Mandel et al., 2004). Our study shows that
EGCG promotes nonamyloidogenic APP processing in vitro and
in vivo, and that it accomplishes this by promoting -secretase
cleavage of APP. Themechanism for increased -secretase cleav-
age activity by an induction of TACE appears transient as shown
in Figure 3. In addition, we measured TACE protein levels in
EGCG- versus PBS-treated Tg APPsw mice using Western blot
analysis and observed that the expression of TACE was not sig-
nificantly altered in brain homogenates derived from EGCG-
treated TgAPPswmicewhen comparedwith control PBS-treated
mice (data not shown). These data suggest that, on a chronic
EGCG treatment basis in vivo, elevated -secretase cleavage ac-
tivity may not require an increase in TACE protein expression.
We intend to fully explore thismechanismof elevated-secretase
activity in vivo in a future study.
It is well known that TACE is a multifunctional molecule that
has been shown to be critically involved in TNF- maturation
associated with proinflammatory responses (Moro et al., 2003).
Additionally, TACE has been identified as a key -secretase can-
didate molecule, and our data suggest that TACE is responsible
for the increased -secretase cleavage of APP observed after
EGCG treatment of SweAPP N2a cells.
Because TACE has not been shown to exhibit substrate pref-
erence for TNF- versus APP, we wondered whether EGCG, by
increasing TACE levels, could promote TNF- maturation and
release in cultured primarymurinemicroglial cells. Interestingly,
despite the observation that TACE transient expression increases
with EGCG treatment, we saw no associated elevation of TNF-
levels in cultured media of primary microglial cells (data not
shown). This observation is consistent with other reports, in
which EGCG treatment actually inhibits TNF- expression and
subsequently neuronal damage (Suganuma et al., 2000; Li et al.,
2004). Because microglia must first undergo coordinated activa-
tion in response to innate immune stimuli to cleave pro-TNF-
and subsequently secrete TNF-, a likely explanation for why
EGCG does not elicit TNF- release from murine microglia is
that it does not trigger microglial activation and may in fact be
immunosuppressive. Based on the data presented in our study of
cultured neurons and neuron-like cells and in vivo in Tg APPsw
mice, it is now possible to identify and dissect the mechanism
through which EGCG exerts its anti-amyloidogenic effects.
A previous study showed that EGCG might act as a -secretase
inhibitor in a cell-free system (Jeon et al., 2003), raising the possibil-
ity thatEGCG-mediated inhibitionofAgenerationmaybeaccom-
plished via blockade of BACE activity. To address this possibility, we
cotreated SweAPP N2a cells with the BACE inhibitor, -secretase
inhibitor II.Results showthat treatmentwith-secretase inhibitor II
at a dose range reported to block -secretase activity (0.5–1.5 M)
(Abbenante et al., 2000) failed to mimic (data not shown) in-
creased -CTF and sAPP- levels after EGCG treatment as
shown in Figure 2, a and b. However, TAPI-1, a TACE inhibitor
(Slack et al., 2001), significantly attenuated the effect of EGCGon
promoting-secretase cleavage of APP (Fig. 3d,e). In addition, as
shown in Figures 3b and 4d, EGCG treatmentmarkedly increased
-secretase cleavage activity both in vitro and in vivo but did not
decrease -secretase cleavage activity. Rather, it appears that
there may actually be a slight increase in -secretase cleavage
activity, as depicted in Figure 2, a and c. This increase may be an
indication of the extent of competition for APP between the two
pathways or an attempt toward homeostasis. However, because
of the sheer amount of -secretase cleavage as illustrated by
-CTF/-CTF ratios in Figure 2, a and c, and relatively un-
changed -secretase cleavage (Fig. 3b), the nonamyloidogenic
pathway seems to be the default cascade and, certainly after
EGCG treatment, dominates APP proteolysis. Moreover, in two
other studies (Levites et al., 2002, 2003), EGCG was found to
modulate PKC activity and to consequently increase secreted lev-
els of sAPP-, further supporting this conclusion. However,
these studies failed to measure the effects of EGCG on A gener-
ation, which is important given that secretion of sAPP- can be
regulated independently of A production (Rossner et al., 2000).
Our data show that EGCG both promotes -secretase activity
and attenuates A production, thereby augmenting nonamyloi-
dogenic APP processing.
Green tea contains numerous polyphenolic flavonoids, and
studies that have shown therapeutic benefits of green tea gener-
ally do not identify the active component(s) responsible. We
found that EGCG confers nonamyloidogenic processing of APP;
yet, the observation that other flavonoids, including GC and C,
can actually oppose this effect of EGCG (Figs. 1c, 2f) suggests that
the mixture of these polyphenolic flavonoids as found in whole
green teamay actually oppose ormask the beneficial properties of
EGCG. This may explain why research involving green tea ex-
tracts or combinations of flavonoids results with such variable
findings (Chung et al., 2003). These observations showing that
EGCG promotes-secretase activitymay lead to the creation of a
new generation of the green tea extract yielding the greatest ther-
apeutic benefit for AD. Although we found that pure EGCG re-
duces A generation in vivo, it is still unclear whether equivalent
doses in humans would be safe and effective. Based on a previous
safety and pharmacokinetic study, it is likely that a daily 1500–
1600 mg bolus of EGCG in humans will approximately achieve
levels similar to those in sera of EGCG (20 mg/kg) intraperitone-
ally injectedmice (Chow et al., 2003). Although not administered
on a chronic basis, oral doses of similar magnitudes have been
used in a clinical trial (Ullmann et al., 2003). Thus, our data
prompt the need for future clinical trials with pure EGCG or its
analogs, which demonstrate more effective -secretase activity-
enhancing properties and/or have better bioavailability.
Structure-activity relationship studies are currently underway in
our laboratory to determine the feasibility of these potentially
promising therapeutic approaches.
When taken together, our data have shown that EGCG treat-
4
(Figure legend continued.) A1–40, 42 (b) and insoluble A1–40, 42 prepared with 5 M guanidine (c) were analyzed by ELISA. Data are presented as mean 1 SEM of A1–40 or A1–42 (pg/mg
protein) separately. For b and c, a t test revealed a significant between-groups difference for either soluble or insoluble A1–40,42 ( p 0.001 for each comparison). d,-,-, and -secretase
cleavage activities were analyzed by secretase cleavage activity assays. Data are presented as mean 1 SEM of fluorescence units/mg protein. A t test revealed a significant difference between
EGCG- and PBS-treated Tg APPsw mice for-secretase activity ( p 0.001). e, Mouse brain coronal paraffin sections were stained with anti-human A antibody (4G8). Left, Control PBS-treated
mice. Right, EGCG-treated mice. The top panels are from the cingulate cortex (CC), the middle panels are from the hippocampus (H), and the bottom panels are from the entorhinal cortex (EC). f,
Percentages of 4G8-immunoreactive A plaques (mean 1 SEM)were calculated by quantitative image analysis, and reduction for each brain region is indicated.g, Mouse brain sections from the
indicated brain regions were stained with thioflavin S. Left, Control PBS-treated mice. Right, EGCG-treated mice. h, Percentage of thioflavin S plaques (mean 1 SEM) were quantified by image
analysis, and reduction for each brain region is indicated. A t test for independent samples revealed significant differences ( p 0.005) between groups for each brain region examined in f and h.
Scale bar, 50m.
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ment leads to a reduction of A levels in both SweAPP N2a cells
and Tg APPsw mouse-derived primary neuronal cells. Further-
more, we found that-CTF generation and sAPP- secretion are
markedly increased in these cells after EGCG treatment, effects
that are correlated with elevated -secretase cleavage activity. To
demonstrate the in vivo therapeutic relevance of these observa-
tions, we intraperitoneally administered EGCG to TgAPPswmice
and found a significant reduction in cerebral A levels concom-
itant with reduced -amyloid plaques. In addition to intraperi-
toneal administration, intracerebroventricular injection of
EGCG into Tg APPsw mice shows comparable reduction of cere-
bral A levels associated with increased -secretase cleavage ac-
tivity, suggesting that the therapeutic effects of peripherally ad-
ministered EGCG are mainly derived from direct CNS action of
the compound. If A pathology in this transgenic model is rep-
resentative of disease pathology in the clinical syndrome, then
EGCG administration to AD patients might be an effective pro-
phylactic strategy for reduction of cerebral amyloidosis.
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